FY2029 Earnings Forecast for ABVX Issued By Leerink Partnrs

ABIVAX Société Anonyme (NASDAQ:ABVX) – Stock analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of ABIVAX Société Anonyme in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith forecasts that the company will post earnings of ($0.17) per share for the year. The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.92) per share.

A number of other research firms have also recently commented on ABVX. Citizens Jmp upgraded ABIVAX Société Anonyme to a “strong-buy” rating in a research report on Wednesday, December 4th. JMP Securities reissued a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $38.67.

ABIVAX Société Anonyme Price Performance

NASDAQ ABVX opened at $6.30 on Thursday. ABIVAX Société Anonyme has a 1-year low of $5.49 and a 1-year high of $17.02. The business’s fifty day moving average price is $7.03 and its 200-day moving average price is $9.48.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. GAMMA Investing LLC bought a new stake in ABIVAX Société Anonyme during the fourth quarter valued at about $29,000. R Squared Ltd bought a new stake in ABIVAX Société Anonyme during the 4th quarter valued at approximately $36,000. BNP Paribas Financial Markets lifted its holdings in ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after purchasing an additional 5,900 shares in the last quarter. Walleye Capital LLC boosted its stake in ABIVAX Société Anonyme by 45.8% in the 3rd quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares during the period. Finally, abrdn plc grew its holdings in ABIVAX Société Anonyme by 167.7% during the 3rd quarter. abrdn plc now owns 316,431 shares of the company’s stock valued at $3,645,000 after buying an additional 198,225 shares in the last quarter. Hedge funds and other institutional investors own 47.91% of the company’s stock.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.